Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Acquires U.S. Rights To Nycomed's Oral COPD Drug Daxas

This article was originally published in The Pink Sheet Daily

Executive Summary

After long development haul, PDE-4 inhibitor finally gets adopted by a commercial parent, ahead of approval.

Related Content

Forest/Nycomed's Daliresp Reaches The Market, But For Fewer Patients Than Expected
Daxas Approved In EU With Narrow Indication
FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote
Forest's Daxas Is Safe And Is Effective, But Not Both, Panel Finds
For Forest, No Single Silver Bullet But Many Opportunities
For Forest, No Single Silver Bullet But Many Opportunities
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
Almirall Signs Up Forest For Once-Daily LABA
Cumberland Pharmaceuticals Raises $85 Million In IPO
AstraZeneca’s Symbicort On Advair’s Heels With COPD Approval





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts